Annual CFF
$4.42 M
+$464.60 K+11.75%
01 July 2024
Summary:
BriaCell Therapeutics annual cash flow from financing activities is currently $4.42 million, with the most recent change of +$464.60 thousand (+11.75%) on 01 July 2024. During the last 3 years, it has fallen by -$60.58 million (-93.20%). BCTX annual CFF is now -93.20% below its all-time high of $65.00 million, reached on 31 July 2021.BCTX Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFF
$4.42 M
+$4.42 M+100.00%
01 July 2024
Summary:
BriaCell Therapeutics quarterly cash flow from financing activities is currently $4.42 million, with the most recent change of +$4.42 million (+100.00%) on 01 July 2024. Over the past year, it has increased by +$4.42 million (+100.00%). BCTX quarterly CFF is now -88.46% below its all-time high of $38.29 million, reached on 31 July 2021.BCTX Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFF
$4.42 M
+$418.90 K+10.47%
01 July 2024
Summary:
BriaCell Therapeutics TTM cash flow from financing activities is currently $4.42 million, with the most recent change of +$418.90 thousand (+10.47%) on 01 July 2024. Over the past year, it has increased by +$417.30 thousand (+10.43%). BCTX TTM CFF is now -93.20% below its all-time high of $65.00 million, reached on 31 July 2021.BCTX TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
BCTX Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +11.8% | +100.0% | +10.4% |
| 3 y3 years | -93.2% | +100.0% | -93.2% |
| 5 y5 years | +81.2% | +520.9% | +45.2% |
BCTX Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -93.2% | +218.1% | at high | +189.2% | -93.2% | +216.6% |
| 5 y | 5 years | -93.2% | +218.1% | -88.5% | +189.2% | -93.2% | +216.6% |
| alltime | all time | -93.2% | +218.1% | -88.5% | +189.2% | -93.2% | +216.6% |
BriaCell Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| July 2024 | $4.42 M(+11.7%) | $4.42 M(>+9900.0%) | $4.42 M(+10.5%) |
| Apr 2024 | - | $0.00(0.0%) | $4.00 M(-0.0%) |
| Jan 2024 | - | $0.00(0.0%) | $4.00 M(0.0%) |
| Oct 2023 | - | $0.00(-100.0%) | $4.00 M(+1.2%) |
| July 2023 | $3.95 M(-205.7%) | $4.00 M(>+9900.0%) | $3.95 M(-2024.2%) |
| Apr 2023 | - | $1600.00(>+9900.0%) | -$205.50 K(-117.7%) |
| Jan 2023 | - | $0.00(-100.0%) | $1.16 M(-130.7%) |
| Oct 2022 | - | -$47.30 K(-70.4%) | -$3.79 M(+1.3%) |
| July 2022 | -$3.74 M(-105.8%) | -$159.80 K(-111.7%) | -$3.74 M(-110.8%) |
| Apr 2022 | - | $1.37 M(-127.7%) | $34.71 M(-42.0%) |
| Jan 2022 | - | -$4.95 M(<-9900.0%) | $59.80 M(-8.0%) |
| Oct 2021 | - | $0.00(-100.0%) | $64.97 M(-0.0%) |
| July 2021 | $65.00 M(+5436.0%) | $38.29 M(+44.7%) | $65.00 M(+140.8%) |
| Apr 2021 | - | $26.46 M(>+9900.0%) | $26.99 M(+4754.7%) |
| Jan 2021 | - | $214.60 K(+691.9%) | $556.00 K(+13.6%) |
| Oct 2020 | - | $27.10 K(-90.6%) | $489.50 K(-58.3%) |
| July 2020 | $1.17 M(-51.9%) | $288.20 K(+1004.2%) | $1.17 M(+6.2%) |
| Apr 2020 | - | $26.10 K(-82.4%) | $1.11 M(-65.4%) |
| Jan 2020 | - | $148.10 K(-79.2%) | $3.19 M(+4.9%) |
| Oct 2019 | - | $711.70 K(+223.9%) | $3.04 M(+24.8%) |
| July 2019 | $2.44 M(-40.0%) | $219.70 K(-89.6%) | $2.44 M(+47.1%) |
| Apr 2019 | - | $2.11 M(<-9900.0%) | $1.66 M(-51.6%) |
| Jan 2019 | - | -$200.00(-100.2%) | $3.42 M(-6.8%) |
| Oct 2018 | - | $106.70 K(-119.0%) | $3.68 M(-9.5%) |
| July 2018 | $4.06 M(+74.7%) | -$561.10 K(-114.5%) | $4.06 M(-15.6%) |
| Apr 2018 | - | $3.88 M(+1442.0%) | $4.81 M(+154.1%) |
| Jan 2018 | - | $251.50 K(-48.9%) | $1.89 M(+12.4%) |
| Oct 2017 | - | $492.50 K(+163.1%) | $1.68 M(-27.6%) |
| July 2017 | $2.32 M(+189.9%) | $187.20 K(-80.5%) | $2.32 M(+10.4%) |
| Apr 2017 | - | $961.40 K(+2135.8%) | $2.11 M(+6.4%) |
| Jan 2017 | - | $43.00 K(-96.2%) | $1.98 M(+2.2%) |
| Oct 2016 | - | $1.13 M(-3587.1%) | $1.94 M(+141.3%) |
| July 2016 | $801.90 K | -$32.50 K(-103.9%) | $801.90 K(+49.7%) |
| Apr 2016 | - | $834.40 K(>+9900.0%) | $535.60 K(<-9900.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jan 2016 | - | $0.00(0.0%) | -$400.00(-100.0%) |
| Oct 2015 | - | $0.00(-100.0%) | $1.59 M(0.0%) |
| July 2015 | $1.59 M(-0.7%) | -$298.80 K(-200.1%) | $1.59 M(-54.5%) |
| Apr 2015 | - | $298.40 K(-81.2%) | $3.49 M(+9.4%) |
| Jan 2015 | - | $1.59 M(>+9900.0%) | $3.19 M(+99.3%) |
| Oct 2014 | - | $0.00(-100.0%) | $1.60 M(0.0%) |
| July 2014 | $1.60 M(>+9900.0%) | $1.60 M(>+9900.0%) | $1.60 M(>+9900.0%) |
| Oct 2013 | - | $0.00(0.0%) | $0.00(0.0%) |
| July 2013 | $0.00(-100.0%) | $0.00(0.0%) | $0.00(-100.0%) |
| Oct 2012 | - | $0.00(-100.0%) | -$200.00(-100.8%) |
| July 2012 | $25.00 K(-99.6%) | -$500.00(-200.0%) | $24.90 K(-346.5%) |
| Apr 2012 | - | $500.00(-350.0%) | -$10.10 K(-100.1%) |
| Jan 2012 | - | -$200.00(-100.8%) | $6.74 M(-0.0%) |
| Oct 2011 | - | $25.10 K(-170.7%) | $6.74 M(+0.1%) |
| July 2011 | $6.73 M(+414.8%) | -$35.50 K(-100.5%) | $6.73 M(-0.1%) |
| Apr 2011 | - | $6.75 M(>+9900.0%) | $6.74 M(+410.0%) |
| Jan 2011 | - | $200.00(-98.7%) | $1.32 M(-0.2%) |
| Oct 2010 | - | $15.70 K(-150.2%) | $1.32 M(+1.2%) |
| July 2010 | $1.31 M(+80.6%) | -$31.30 K(-102.3%) | $1.31 M(-30.6%) |
| Apr 2010 | - | $1.34 M(>+9900.0%) | $1.88 M(+159.2%) |
| Jan 2010 | - | $2800.00(>+9900.0%) | $726.80 K(+0.4%) |
| Oct 2009 | - | $0.00(-100.0%) | $724.00 K(0.0%) |
| July 2009 | $724.00 K(>+9900.0%) | $545.30 K(+205.1%) | $724.00 K(+305.1%) |
| Apr 2009 | - | $178.70 K(>+9900.0%) | $178.70 K(>+9900.0%) |
| Jan 2009 | - | $0.00(0.0%) | $0.00(0.0%) |
| Oct 2008 | - | $0.00(0.0%) | $0.00(0.0%) |
| July 2008 | $0.00(-100.0%) | $0.00(0.0%) | $0.00(-100.0%) |
| Apr 2008 | - | $0.00(0.0%) | $16.00 K(-61.7%) |
| Jan 2008 | - | $0.00(0.0%) | $41.80 K(+95.3%) |
| Oct 2007 | - | $0.00(-100.0%) | $21.40 K(-95.1%) |
| July 2007 | $439.30 K(+396.9%) | $16.00 K(-38.0%) | $439.30 K(+3.8%) |
| Apr 2007 | - | $25.80 K(-226.5%) | $423.30 K(+6.5%) |
| Jan 2007 | - | -$20.40 K(-104.9%) | $397.50 K(-4.9%) |
| Oct 2006 | - | $417.90 K | $417.90 K |
| July 2006 | $88.40 K | - | - |
FAQ
- What is BriaCell Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for BriaCell Therapeutics?
- What is BriaCell Therapeutics annual CFF year-on-year change?
- What is BriaCell Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for BriaCell Therapeutics?
- What is BriaCell Therapeutics quarterly CFF year-on-year change?
- What is BriaCell Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for BriaCell Therapeutics?
- What is BriaCell Therapeutics TTM CFF year-on-year change?
What is BriaCell Therapeutics annual cash flow from financing activities?
The current annual CFF of BCTX is $4.42 M
What is the all time high annual CFF for BriaCell Therapeutics?
BriaCell Therapeutics all-time high annual cash flow from financing activities is $65.00 M
What is BriaCell Therapeutics annual CFF year-on-year change?
Over the past year, BCTX annual cash flow from financing activities has changed by +$464.60 K (+11.75%)
What is BriaCell Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of BCTX is $4.42 M
What is the all time high quarterly CFF for BriaCell Therapeutics?
BriaCell Therapeutics all-time high quarterly cash flow from financing activities is $38.29 M
What is BriaCell Therapeutics quarterly CFF year-on-year change?
Over the past year, BCTX quarterly cash flow from financing activities has changed by +$4.42 M (+100.00%)
What is BriaCell Therapeutics TTM cash flow from financing activities?
The current TTM CFF of BCTX is $4.42 M
What is the all time high TTM CFF for BriaCell Therapeutics?
BriaCell Therapeutics all-time high TTM cash flow from financing activities is $65.00 M
What is BriaCell Therapeutics TTM CFF year-on-year change?
Over the past year, BCTX TTM cash flow from financing activities has changed by +$417.30 K (+10.43%)